Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 1/20 | 0.37 |
| ▸ | GLP1R | P43220 | 8/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.33 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
| ▸ | NPY1R | P25929 | 1/20 | 0.33 |
| ▸ | NPY4R | P50391 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20797913 | 1.00 | C3AR1 (0.37) | C3AR1GLP1RMEN1GAAKMT2A | |
| SCHEMBL1344935 | 0.92 | C3AR1 (0.38) | C3AR1MEN1GAAKMT2ANPY1R | |
| SCHEMBL22170883 | 0.90 | NPY4R (0.39) | MEN1KMT2ANPY1RNPY4RTSHR | |
| SCHEMBL20798198 | 0.86 | C3AR1 (0.50) | C3AR1GLP1RDGAT1 | |
| SCHEMBL20798196 | 0.86 | C3AR1 (0.50) | C3AR1GLP1RDGAT1 | |
| SCHEMBL22170833 | 0.86 | TSHR (0.34) | KMT2ATLR2NPY1RNPY4RTSHR | |
| SCHEMBL20797931 | 0.86 | C3AR1 (0.50) | C3AR1GLP1RDGAT1 | |
| SCHEMBL20797799 | 0.86 | C3AR1 (0.50) | C3AR1GLP1RDGAT1 | |
| SCHEMBL28407165 | 0.86 | TSHR (0.34) | KMT2ATLR2NPY1RNPY4RTSHR | |
| SCHEMBL22170830 | 0.85 | C3AR1 (0.51) | C3AR1GLP1RNPY1RNPY4REPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3678700-B1 | COMPOUNDS FOR REDUCING THE VISCOSITY OF BIOLOGICAL FORMULATIONS | MERCK SHARP & DOHME LLC (US) | 2024-06-19 | — | — | EP | disclosed |
| US-20220378916-A1 | COMPOUNDS FOR REDUCING THE VISCOSITY OF BIOLOGICAL FORMULATIONS | MERCK SHARP & DOHME LLC (US) | 2022-12-01 | — | — | US | disclosed |
| EP-3678700-A1 | COMPOUNDS FOR REDUCING THE VISCOSITY OF BIOLOGICAL FORMULATIONS | Merck Sharp & Dohme Corp. (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20200206350-A1 | COMPOUNDS FOR REDUCING THE VISCOSITY OF BIOLOGICAL FORMULATIONS | MERCK SHARP & DOHME CORP. (US) | 2020-07-02 | — | — | US | disclosed |
| US-20200206350-A1 | COMPOUNDS FOR REDUCING THE VISCOSITY OF BIOLOGICAL FORMULATIONS | MERCK SHARP & DOHME CORP. (US) | 2020-07-02 | — | — | US | disclosed |
| CN-111107873-A | Compounds for reducing the viscosity of biologicals | 默沙东公司 | 2020-05-05 | — | — | CN | disclosed |
| WO-2019050780-A1 | COMPOUNDS FOR REDUCING THE VISCOSITY OF BIOLOGICAL FORMULATIONS | MERCK SHARP & DOHME CORP. (US) | 2019-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206350-A1 | COMPOUNDS FOR REDUCING THE VISCOSITY OF BIOLOGICAL FORMULATIONS | CD274, PDCD1, JAK1 | C3AR1 57/4885GLP1R 67/4885MEN1 2947/4885 |
| US-20220378916-A1 | COMPOUNDS FOR REDUCING THE VISCOSITY OF BIOLOGICAL FORMULATIONS | CD274, PDCD1, JAK1 | C3AR1 65/4885GLP1R 84/4885MEN1 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.